Stryker Corporation $SYK Shares Acquired by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc boosted its holdings in Stryker Corporation (NYSE:SYK) by 38.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,903 shares of the medical technology company’s stock after purchasing an additional 9,144 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in Stryker were worth $12,162,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SYK. Tufton Capital Management boosted its stake in shares of Stryker by 11.6% during the third quarter. Tufton Capital Management now owns 959 shares of the medical technology company’s stock worth $354,000 after buying an additional 100 shares during the period. Monte Financial Group LLC raised its stake in Stryker by 10.8% during the 3rd quarter. Monte Financial Group LLC now owns 3,918 shares of the medical technology company’s stock valued at $1,448,000 after acquiring an additional 383 shares during the last quarter. Copia Wealth Management raised its stake in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after acquiring an additional 69 shares during the last quarter. Values Added Financial LLC lifted its position in Stryker by 3.6% during the 3rd quarter. Values Added Financial LLC now owns 1,685 shares of the medical technology company’s stock worth $623,000 after acquiring an additional 59 shares during the period. Finally, Cullen Frost Bankers Inc. grew its stake in shares of Stryker by 1.3% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 64,581 shares of the medical technology company’s stock valued at $23,874,000 after purchasing an additional 860 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 522,118 shares of company stock worth $185,381,932 in the last ninety days. Insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $410.00 price objective on shares of Stryker in a research report on Friday, November 14th. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a report on Friday, December 19th. Citigroup cut their price target on shares of Stryker from $455.00 to $420.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. Finally, Evercore ISI set a $390.00 target price on Stryker in a research note on Monday, January 5th. Fourteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $430.00.

Stryker Trading Down 1.1%

Shares of SYK stock opened at $354.74 on Monday. The stock has a market cap of $135.66 billion, a P/E ratio of 46.62, a P/E/G ratio of 2.28 and a beta of 0.89. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The business has a fifty day simple moving average of $359.77 and a 200-day simple moving average of $372.68.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the prior year, the company earned $2.87 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio is 46.25%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.